Sign In
4 Apr 2013 09:03
Cathay International Holdings Limited
("Cathay" or the "Company")
Grant of Share Options
Hong Kong, 4April 2013 - Cathay International Holdings Ltd. (LSE: CTI.L), an investment holding company and a leading investor in the growing healthcare sector in the People's Republic of China, today announces that on 27 March 2013, the Company granted 3,490,000 options under a share option plan (the "Share Option Plan") approved by shareholders of the Company on 3 June 2010. The 3,490,000optionsgranted to certain members of the Group's management and employees represent approximately 19.03% of the options currently available under the Share Option Plan. Of the 3,490,000options granted, the share options granted to directors and senior executives of the Group are as follows:
Name | Position | Number of share options granted |
Mr. Lee Jin-Yi | Chief Executive Officer | 2,000,000 |
Mr. Eric Siu Ka Chi | Finance Director | 330,000 |
Mr. Patrick Sung | Director and Controller | 270,000 |
Ms. Rebecca Yip Pui Ling | Company Secretary | 40,000 |
The exercise price of the options of 32.55pence per share equates to the average closing mid-market price of the Company's common shares for the 30 trading days immediately prior to the date of grant. The options have a three years vesting period and are exercisable on or before the fifth anniversary of the date of the grant, subject to certain exercise conditions aligned to the Group's results and performance.
- ENDS -
For further enquiries, please contact:
Cathay International Holdings Limited Eric Siu (Finance Director) Patrick Sung (Director and Controller) |
Tel: +852 2828 9289 |
M:Communications Mary-Jane Elliott / Amber Bielecka / Claire Dickinson |
Tel: +44 (0)20 7920 2330 |
About Cathay
Cathay International Holdings Limited (CTI.L) is an investment holding company and a leading investor in the growing healthcare sector in the People's Republic of China ("PRC"). Taking advantage of the strong and growing domestic demand for high quality healthcare products in China, Cathay aims to identify investment opportunities with emphasis on high growth healthcare markets and build them into market sector leaders, with a clear exit strategy. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen Group, China's leading specialty pharmaceutical company focused on rheumatology and Haotian Group, a company engaged in the manufacture, marketing and sale of key active ingredients for healthcare products, including dietary supplement inositol. To complement its healthcare portfolio, Cathay has a research and product development business focused on bringing new products to the growing Chinese market.
The Group employs more than 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a private equity investment arm focused on minority investment opportunities and a hotel investment.
For more information please visit the Company's website: www.cathay-intl.com.hk
Follow the stocks
